Study Links Nexavar To Hypertension Risk

Law360, New York (January 23, 2008, 12:00 AM EST) -- A new study is warning about the potential side effects of Nexavar, maintaining that the drug used to treat kidney and liver cancer can trigger a significant spike in blood pressure.

On Tuesday, the medical journal Lancet Oncology published a study on the effects of the chemotherapy drug, also known by the scientific name sorafenib, with the authors urging patients currently taking Nexavar to remain under close watch due to a potential link with hypertension.

The U.S. Food and Drug Administration approved the drug in 2005...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.